Literature DB >> 6958117

Lea blood group substance degradation in the human alimentary tract and urinary Lea in coeliac disease.

D A Evans, W T Donohoe, S Hewitt, B D Linaker.   

Abstract

The Lewis (Lea) blood group substance in alimentary tract liquids is a large molecule. Ileal and jejunal mucosal preparations can act upon it to produce dialysable serologically active Lea. Alimentary tract bacteria cannot produce a similar effect. Plasma, serum and urinary Lea are principally in the form of a dialysable moiety. It is suggested that this dialysable form is produced by mucosal degradation of large-molecule Lea in the alimentary tract. The small-molecule Lea is absorbed, transported in the plasma and then excreted. Both secretor and non-secretor patients with duodenal ulcer and inflammatory bowel disease have normal urinary Lea titres. Non-secretor coeliac patients who have not regenerated normal jejunal mucosa on treatment have significantly reduced urinary Lea titres when compared with healthy individuals. One non-secretor coeliac patient who had regenerated a normal jejunal mucosa on treatment had a normal urinary Lea titre. Coeliac patients have normal titres of salivary Lea.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6958117     DOI: 10.1111/j.1423-0410.1982.tb00010.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  3 in total

1.  The Lewis blood group system in liver transplantation.

Authors:  G Ramsey; J Wolford; D J Boczkowski; F W Cornell; P Larson; T E Starzl
Journal:  Transplant Proc       Date:  1987-12       Impact factor: 1.066

Review 2.  Survey of the human acetylator polymorphism in spontaneous disorders.

Authors:  D A Evans
Journal:  J Med Genet       Date:  1984-08       Impact factor: 6.318

3.  Blood group lewis phenotype on erythrocytes and in saliva in alcoholic pancreatitis and chronic liver disease.

Authors:  L Stigendal; R Olsson; L Rydberg; B E Samuelsson
Journal:  J Clin Pathol       Date:  1984-07       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.